Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5918687 | 1.00 | NAAA (0.47) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL615494 | 1.00 | NAAA (0.47) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL2984689 | 1.00 | NAAA (0.47) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL611992 | 1.00 | NAAA (0.47) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL5315110 | 1.00 | NAAA (0.47) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL157764 | 1.00 | NAAA (0.47) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL2980882 | 0.98 | NAAA (0.48) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL19025364 | 0.98 | NAAA (0.48) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL17433676 | 0.98 | NAAA (0.48) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL730515 | 0.98 | NAAA (0.48) | NAAARAD52NPSR1EPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021148249-A1 | NEW COMPOSITION AS SHAVING PREPARATION | BEIERSDORF AG (DE) | 2021-07-29 | — | — | WO | claimed |
| CN-102006872-A | Ophthalmic preparation containing a pyridinol derivate | MARVEL LIFESCIENCES LTD | 2011-04-06 | — | — | CN | claimed |
| EP-1364651-B1 | Pharmaceutical composition with deswelling properties | SEBAPHARMA GMBH & CO KG (DE) | 2005-11-02 | — | — | EP | claimed |
| CN-117529306-A | Nicotinamide Adenine Dinucleotide (NAD) compositions, methods of making and methods of using the same | 索维达解决方案有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117479945-A | Large conductance potassium channel modulators, compositions thereof, methods of making and methods of using the same | 依那拉治疗股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| WO-2023250141-A2 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | ENALARE THERAPEUTICS INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-4255383-A1 | USE OF DIHYDROMYRICETIN AS EPIGENETIC COSMETIC OR DERMATOLOGICAL SKIN CARE AGENT | Beiersdorf AG (DE) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023192602-A2 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| CN-116782923-A | Scar treatment composition | 塔普克斯制药公司 | 2023-09-19 | — | — | CN | disclosed |
| US-11752078-B2 | Oil-in-water emulsions containing 4-hydroxyacetophenone and anionic emulsifiers | SYMRISE AG (DE) | 2023-09-12 | — | — | US | disclosed |
| CN-116710081-A | Scar treatment composition | 塔普克斯制药公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20030180278-A1 | Use of a combination of active substances containing bioquinones for the production of cosmetic or dermatological preparations | GS DEVELOPMENT A.B. (SE) | 2003-09-25 | — | — | US | disclosed |
| US-20030180277-A1 | Use of bioquinones for producing cosmetic or dermatological preparations for treating the hair and scalp | GS DEVELOPMENT AB (SE) | 2003-09-25 | — | — | US | disclosed |
| US-20020119344-A1 | Multilayer; backing containing carbon black | FUJIFILM HOLDINGS CORPORATION (JP) | 2002-08-29 | — | — | US | disclosed |
| CN-1308318-A | Magnetic record medium | TORAY INDUSTRIES (JP) | 2001-08-15 | — | — | CN | disclosed |
| EP-0563405-B1 | MAGNETIC RECORDING MEDIUM | HITACHI MAXELL (JP) | 2001-07-04 | — | — | EP | disclosed |
| EP-1067518-A2 | Magnetic recording medium | SONY CORPORATION (JP) | 2001-01-10 | — | — | EP | disclosed |
| US-5789062-A | Magnetic recording medium | HITACHI MAXELL, LTD. (JP) | 1998-08-04 | — | — | US | disclosed |
| EP-0563405-A1 | MAGNETIC RECORDING MEDIUM | Hitachi Maxell Ltd. (JP) | 1993-10-06 | — | — | EP | disclosed |
| US-4239832-A | TYPEWRITER RIBBON THE IMPRESSIONS OF WHICH CAN BE CORRECTED IMMEDIATELY BUT NOT AFTER A SHORT PERIOD OF TIME | EATON ALLEN CORP. (US) | 1980-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030180278-A1 | Use of a combination of active substances containing bioquinones for the production of cosmetic or dermatological preparations | SDHA, SDHB, SLC25A20 | NAAA 1164/4885RAD52 1111/4885NPSR1 3089/4885 |
| US-11752078-B2 | Oil-in-water emulsions containing 4-hydroxyacetophenone and anionic emulsifiers | HSD17B10, GNPAT, HSD17B4 | NAAA 1049/4885RAD52 1589/4885NPSR1 2892/4885 |
| US-20030180277-A1 | Use of bioquinones for producing cosmetic or dermatological preparations for treating the hair and scalp | SDHA, SDHB, SLC25A20 | NAAA 973/4885RAD52 242/4885NPSR1 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.